Carmell Corp. Announces Board Changes and Officer Compensation Adjustments
Ticker: XAGEW · Form: 8-K · Filed: Jul 29, 2024 · CIK: 1842939
| Field | Detail |
|---|---|
| Company | Carmell Corp (XAGEW) |
| Form Type | 8-K |
| Filed Date | Jul 29, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $11.50, $100 million, $300,000, $700,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, officer-compensation, corporate-governance
TL;DR
Carmell Corp. shakes up the board and adjusts exec pay. Big changes coming?
AI Summary
Carmell Corp. announced on July 29, 2024, a change in its board of directors, with the election of new directors and changes in officer compensation arrangements. The company, formerly Carmell Therapeutics Corp., is involved in the surgical and medical instruments and apparatus industry.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board and officer changes, especially when coupled with compensation adjustments, can introduce uncertainty about future strategic direction and operational stability.
Key Numbers
- 001-40228 — SEC File Number (Identifies the company's filings with the SEC.)
- 86-1645738 — IRS Number (Company's Employer Identification Number.)
Key Players & Entities
- Carmell Corp. (company) — Registrant
- July 29, 2024 (date) — Date of Report
- Carmell Therapeutics Corp. (company) — Former Company Name
- ALPHA HEALTHCARE ACQUISITION CORP III (company) — Former Company Name
- Delaware (jurisdiction) — State of Incorporation
FAQ
What specific changes were made to the board of directors?
The filing indicates the election of directors and departure of certain officers, but the specific names and details of these changes are not provided in the excerpt.
What are the details of the compensatory arrangements for certain officers?
The filing mentions adjustments to compensatory arrangements for certain officers, but the specific details of these arrangements are not included in the provided text.
When did Carmell Corp. change its name from Carmell Therapeutics Corp.?
Carmell Corp. changed its name from Carmell Therapeutics Corp. on July 27, 2023.
What is Carmell Corp.'s Standard Industrial Classification (SIC) code?
Carmell Corp.'s SIC code is 3841, which corresponds to Surgical & Medical Instruments & Apparatus.
What is the company's primary business address?
The company's business address is 2403 Sidney Street, Suite 300, Pittsburgh, PA 15203.
Filing Stats: 1,256 words · 5 min read · ~4 pages · Grade level 12.5 · Accepted 2024-07-29 08:38:43
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CTCX The Nasdaq Stock Mar
- $11.50 — of Common Stock at an exercise price of $11.50 CTCXW The Nasdaq Stock Market LLC
- $100 million — t have collectively generated more than $100 million in revenue. She currently serves on the
- $300,000 — eceive an initial annual base salary of $300,000. In addition, Ms. Bracken-Ferguson will
- $700,000 — options with a grant date fair value of $700,000, under the Carmell Corporation 2023 Lon
Filing Documents
- ctcx-20240729.htm (8-K) — 52KB
- ctcx-ex10_1.htm (EX-10.1) — 175KB
- ctcx-ex99_1.htm (EX-99.1) — 19KB
- 0000950170-24-087128.txt ( ) — 390KB
- ctcx-20240729.xsd (EX-101.SCH) — 44KB
- ctcx-20240729_htm.xml (XML) — 6KB
01 Other Events
Item 8.01 Other Events. A copy of the press release containing the announcement of Ms. Bracken-Ferguson's appointment as Chief Executive Officer is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description 10.1 Employment Agreement, dated July 23, 2024, by and between Carmell Corporation and Kendra Bracken-Ferguson. 99.1 Press Release, dated July 29, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 29, 2024 By: /s/ Bryan J. Cassaday Bryan J. Cassaday Chief Finanical Officer